| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR8 |
| Uniprot No | P51685 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-355aa |
| 氨基酸序列 | MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGKLLLAVFYCLLFVFSL LGNSLVILVLVVCKKLRSITDVYLLNLALSDLLFVFSFPFQTYYLLDQWV FGTVMCKVVSGFYYIGFYSSMFFITLMSVDRYLAVVHAVYALKVRTIRMG TTLCLAVWLTAIMATIPLLVFYQVASEDGVLQCYSFYNQQTLKWKIFTNF KMNILGLLIPFTIFMFCYIKILHQLKRCQNHNKTKAIRLVLIVVIASLLF WVPFNVVLFLTSLHSMHILDGCSISQQLTYATHVTEIISFTHCCVNPVIY AFVGEKFKKHLSEIFQKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSSS VDYIL |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCR8重组蛋白的3篇参考文献的简要整理：
---
1. **文献名称**: *"Expression, Purification, and Functional Characterization of Recombinant Human CCR8 in Insect Cells"*
**作者**: Smith A, et al.
**摘要**: 该研究通过杆状病毒-昆虫细胞系统成功表达了重组人CCR8蛋白，优化了纯化流程并验证了其与配体CCL1的结合活性，为后续药物筛选提供了可靠工具。
---
2. **文献名称**: *"Structural Insights into CCR8 Recognition by a Monoclonal Antibody Using Recombinant CCR8 Extracellular Domain"*
**作者**: Lee H, et al.
**摘要**: 通过表达CCR8细胞外结构域的重组蛋白，结合X射线晶体学解析了其与治疗性抗体的复合物结构，揭示了抗体结合的关键表位，为癌症免疫治疗提供结构基础。
---
3. **文献名称**: *"Development of a CCR8 Reporter Cell Line Using Recombinant CCR8 and Luciferase Assay"*
**作者**: Wang Y, et al.
**摘要**: 构建了稳定表达重组CCR8的HEK293细胞系，结合荧光素酶报告系统，用于高通量筛选靶向CCR8的激动剂/拮抗剂，验证了其在药物开发中的应用潜力。
---
注：以上文献信息为模拟示例，实际引用时需核对真实文献。如需具体论文，建议通过PubMed或Google Scholar检索关键词“CCR8 recombinant protein expression”、“CCR8 structure-function”等获取。
**Background of CCR8 Recombinant Protein**
CCR8 (C-C chemokine receptor type 8) is a G protein-coupled receptor (GPCR) belonging to the chemokine receptor family, which plays a critical role in immune regulation and inflammatory responses. It is primarily expressed on immune cells, including Th2 cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes. CCR8 interacts with specific ligands, such as CCL1 (chemokine ligand 1), to mediate cell migration, activation, and survival. Its involvement in immune tolerance and tumor microenvironment modulation has drawn significant attention in recent research.
Recombinant CCR8 protein is engineered through molecular cloning techniques, often expressed in mammalian or insect cell systems to ensure proper post-translational modifications and functional integrity. This protein retains the extracellular domains critical for ligand binding and receptor activation, enabling its use in structural studies, ligand-receptor interaction assays, and drug discovery.
In cancer biology, CCR8 is implicated in promoting immunosuppressive environments by recruiting Tregs to tumors, thereby aiding immune evasion. This makes CCR8 a potential therapeutic target, with ongoing studies exploring neutralizing antibodies or small-molecule inhibitors to block its activity. Additionally, CCR8's role in allergic inflammation and autoimmune diseases highlights its broader therapeutic relevance.
The availability of recombinant CCR8 protein facilitates mechanistic studies, high-throughput screening for drug candidates, and the development of targeted immunotherapies. Its application extends to biomarker research, particularly in cancers where CCR8 overexpression correlates with poor prognosis. As research progresses, CCR8 continues to emerge as a pivotal player in bridging innate and adaptive immunity, offering promising avenues for novel treatments in oncology and immune-related disorders.
×
